ArticleThe journal of allergy and clinical immunology. Global2026
MMR and varicella immunization during dupilumab therapy.
Article in The journal of allergy and clinical immunology. Global, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The US Food and Drug Administration recommends deferring administration of live vaccines during dupilumab treatment owing to lack of data on safety and efficacy. Understanding the safety profile of measles, mumps, and rubella (MMR) and varicella administration in children taking dupilumab is important to promote appropriate vaccination. Objective: Our aim was to determine the safety of MMR and varicella immunizations during treatment with dupilumab and the impact of dupilumab on MMR and varicella vaccination rates in early childhood. Methods: We performed a single-center retrospective review of children younger than 9 years who were taking dupilumab and had available vaccination records. The primary outcome measures were vaccine-associated infections, vaccine-associated adverse events, and rate of immunization. Results: Of the 19 patients who received MMR and varicella immunization while taking dupilumab, none experienced severe vaccine-associated events or vaccine-associated infections. One patient reported fever and injection site reaction, and 5 reported a flare of atopic dermatitis (AD). In all, administration of 21 varicella boosters (9.7%) and 25 MMR boosters (11.5%) were delayed because the children were taking dupilumab. There was a significant delay in the age of administration of MMR boosters and varicella boosters when before- and after-dupilumab therapy rates were compared. Conclusion: MMR and varicella immunization may be safe to administer to children undergoing dupilumab therapy. Pausing dupilumab therapy for administration of live vaccines may lead to flare of underlying AD. Further, dupilumab treatment in early childhood may result in decreased and/or delayed vaccination rates for MMR and varicella. Our findings support the recent recommendation that immunizations not be delayed while patients are receiving dupilumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.